Friedreich's ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorderTreatment with SKYCLARYS improved patient function compared to placeboBiogen is leveraging its expertise and capabilities in rare disease to bring this groundbreaking treatment to patients CAMBRIDGE, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) --  Biogen Inc. (NASDAQ:BIIB) announced the European Commission (EC) has authorized SKYCLARYS® (omaveloxolone) for the treatment of Friedreich's ataxia (FA) in adults and ad ...

We expect Biogen (BIIB) to beat expectations when it reports fourth-quarter and full-year 2023 results on Feb 13, before market open. In the last reported quarter, the company delivered an earnings surprise of 9.27%.Factors to ConsiderBiogen’s sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and rising competitive pressure in the MS market. Tecfidera sales have been declining as multiple generic versions of the drug hav ...

Wall Street analysts expect Biogen Inc. (BIIB) to post quarterly earnings of $3.16 per share in its upcoming report, which indicates a year-over-year decline of 22%. Revenues are expected to be $2.46 billion, down 3.4% from the year-ago quarter.Over the last 30 days, there has been a downward revision of 0.4% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timefram ...

Biogen Inc. (BIIB) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on February 13, 2024, might help the stock move higher if these key numbers are better than ...

In the latest trading session, Biogen Inc. (BIIB) closed at $243.72, marking a -1.66% move from the previous day. The stock's change was less than the S&P 500's daily gain of 1.07%. Meanwhile, the Dow gained 0.35%, and the Nasdaq, a tech-heavy index, added 1.74%.The company's shares have seen a decrease of 4.78% over the last month, not keeping up with the Medical sector's gain of 4.02% and the S&P 500's gain of 2.93%.The upcoming earnings release of Biogen Inc. will be of great interest to investors. The c ...

Biogen Inc. (BIIB) announced plans to reprioritize its resources in Alzheimer’s disease (AD). It intends to advance the new Alzheimer’s drug Leqembi (lecanemab-irmb) and to accelerate the development of new treatment modalities.Alzheimer's is a progressive, fatal disease of the brain characterized by a decline in memory, language and other thinking skills, as well as changes in mood and behavior.As part of this reprioritization plan, Biogen will henceforth stop the development and commercialization of its c ...

Biogen on Wednesday said it will discontinue the sale and development of its older and highly controversial Alzheimer's drug Aduhelm to refocus the company's efforts to treat the memory-robbing disease. The biotech company will focus on rolling out Leqembi, a newly approved Alzheimer's drug it developed with the Japanese drugmaker Eisai. It also plans to work on a slate of experimental treatments for the disease. Those drugs represent a new chapter for the company after the polarizing launch and approval of ...

Biogen Inc. BIIB, -0.18% said Wednesday that it will halt the development and commercialization of its Alzheimer’s drug Aduhelm, which drew intense scrutiny of its U.S. regulatory approval process due to concerns about whether its benefits outweighed its risks. The drugmaker said it will continue to advance Leqembi, the Alzheimer’s treatment granted full approval last year by the U.S. Food and Drug Administration and will accelerate development of other potential new treatments. The decision to discontinue ...

Company to reprioritize resources allocated to ADUHELM® (aducanumab-avwa) to advance LEQEMBI® (lecanemab-irmb) and to develop new treatment modalitiesBiogen committed to building a leading Alzheimer's disease franchise to address patient needs CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced plans to reprioritize its resources in Alzheimer's disease (AD), a strategic therapeutic area expected to drive near and long-term growth. The company will continue to advanc ...

In the latest market close, Biogen Inc. (BIIB) reached $247.52, with a +1.1% movement compared to the previous day. This change outpaced the S&P 500's 0.76% gain on the day. Elsewhere, the Dow gained 0.59%, while the tech-heavy Nasdaq added 1.12%.Shares of the company have depreciated by 5.39% over the course of the past month, underperforming the Medical sector's gain of 1.57% and the S&P 500's gain of 2.5%.The upcoming earnings release of Biogen Inc. will be of great interest to investors. The company's e ...